Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

By Zacks Investment ResearchStock MarketsMar 04, 2020 06:30AM ET
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now
By Zacks Investment Research   |  Mar 04, 2020 06:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Avanos Medical, Inc. (NYSE:AVNS) is likely to gain from a solid fourth-quarter show, while sluggishness in the Acute Pain business is a concern.

Shares of this company have declined 34.6% against the industry’s 0.9% rise in a year’s time. The current level also compares unfavorably with the S&P 500 index’s 9.6% rise over the same time frame.

This $1.56-billion medical technology company currently has a Zacks Rank #3 (Hold). Avanos’ earnings are expected to grow 13.3% in the first quarter of 2020. Also, the company has a trailing four-quarter positive earnings surprise of 0.1%, on average.

Let’s take a closer look at the factors that are working in favor of the company right now.

Q4 Earnings & Positive Developments

Avanos reported adjusted earnings per share (EPS) of 34 cents in fourth-quarter 2019, which rose by a penny year over year.

Revenues totaled $189.8 million, up 11.7% on a year-over-year basis.

Notably, the core Chronic Care segment recorded revenues of $113.4 million, up 15.5% year over year. Per management, the upside can be attributed to positive organic sales growth.

Additionally, the Pain Management arm reported net revenues of $76.4 million. The metric improved 6.6% on a year-over-year basis.

That’s not all. Management is optimistic about the FDA clearance of its new 80-Watt COOLIEF Radiofrequency System for neurological lesion procedures. Moreover, the upcoming launch of the company’s next-generation enteral feeding tube Mic-Key is likely to boost the Chronic Care unit.

Management at Avanos confirmed that the company expects lower foreign currency impact in 2020 in comparison to 2019.


Avanos continues to see pressure in its Acute Pain business, which saw a soft fourth quarter. Per management, ON-Q sales declined low-single-digits globally in the quarter. Also, in North America, sales declined low single digits.

Estimates Picture

For 2020, the Zacks Consensus Estimate for revenues is pegged at $739.1 million, indicating an improvement of 6% from the year-ago quarter’s reported figure. For adjusted EPS, the same stands at $1.13, suggesting growth of 5.6% from the year-ago reported figure.

Key Picks

Some better-ranked companies in the broader medical sector include Stryker Corporation (NYSE:SYK) , Accuray Incorporated (NASDAQ:ARAY) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker’s long-term earnings growth is expected at 11.9%. The stock has a Zacks Rank #2.

Accuray’s fiscal fourth-quarter earnings is expected to skyrocket 200%.

IDEXX Laboratories’ first-quarter earnings growth is projected at 5.1%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Stryker Corporation (SYK): Free Stock Analysis Report

Accuray Incorporated (ARAY): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report

Original post

Zacks Investment Research
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

Related Articles

Jani Ziedins
S&P 500: Did You Buy The Bounce? By Jani Ziedins - Oct 20, 2021 2

The S&P 500 surged for the fifth day in a row on Tuesday. The broad benchmark finds itself less than half a percent from all-time highs. Does anyone see a correction because I...

Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email